Latest News
Weekly News Roundup | 29 June 2026
Life science news 29 June 2026: AbbVie and Merck KGaA announce blockbuster acquisitions totalling more than $22 billion, NICE recommends the first disease-modifying therapy for type 1 diabetes for NHS use, and Definium Therapeutics delivers a landmark Phase 3 result...
Latest News
Why I Founded Mesogen: A New Vision for Personalized Regenerative Medicine
For much of my career I have been fascinated by a simple but profound question: What if medicine could restore what disease destroys? Modern medicine has achieved remarkable success in helping patients manage chronic illnesses. We have developed sophisticated drugs,...
Light-Driven Immune Modulation and Its Impact on Autoimmune Therapy
One of the most consistent epidemiological patterns in multiple sclerosis (MS) is its geographic distribution. Rates rise with distance from the equator, where year-round sunlight exposure is lower.[1] For decades, this has pointed to a role for environmental light in...
Merck KGaA Acquires Bio-Techne for $11.3 Billion in Life Science Tools Deal
The Merck KGaA Bio-Techne acquisition values the Minneapolis-based life science tools company at approximately $11.3 billion. Merck KGaA, the German science and technology group, announced on 25 June 2026 that it will acquire Minneapolis-based Bio-Techne Corporation...
Clinical Trials Roundup | 26 June 2026
This week's clinical trial results for 26 June 2026 deliver a landmark psychiatric result, a major oncology setback, and a decisive blow to one of the most watched platforms in regenerative medicine. Definium Therapeutics' DT120 becomes the first lysergide therapy to...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
The Role of the Microbiome in Topical Botanical Applications
The human skin is home to a complex and dynamic ecosystem of microorganisms collectively known as the skin microbiome. This microbial community - comprising bacteria, fungi, and viruses - plays a critical role in maintaining skin health, regulating immune responses,...
Beyond the Screen: Why Spinal Care Must Be Symptom-Led
In an era dominated by high-resolution diagnostics, the field of spinal care faces a profound paradox: while our ability to visualise cellular and structural anatomy has never been more advanced, the clinical efficacy of spinal interventions has not risen in tandem....
New Research Reveals How Toxic Proteins Kill Brain Cells in Dementia
Findings published in Nature Communications point to a previously uncharacterised cell death mechanism that could open new therapeutic targets for slowing neurodegeneration Researchers at King's College London and the UK Dementia Research Institute have identified a...
The ‘Wild West’ of Peptide Medicine and Who’s Qualified to Prescribe
In the medical field, being “authorized” and “qualified” are two very different things. Authorized generally indicates you have the legal right to practice. Qualified means you have the expertise, experience, and skill needed to practice effectively. The distinction...
Finding AF Before It Strikes: The Case for National Screening
There’s a concerning number of Australians living with a dangerous heart rhythm disorder - and many of them have no idea. Atrial fibrillation (AF) is a condition most people have never heard of and that’s a big problem, because it is already a silent cause of stroke. ...
Creative Biolabs Discusses Antibody Library Screening Workflow
Antibody library screening is widely used to identify antibody fragments, such as scFv, Fab, and single-domain antibodies, from large molecular repertoires. Compared with immunization-dependent approaches, library screening can be especially useful for challenging...
CAR-T Therapy Reaches Solid Tumours for the First Time
China's National Medical Products Administration (NMPA) approved satricabtagene autoleucel (satri-cel) on 22 June 2026, making it the world's first CAR-T cell therapy approved for a solid tumour. Developed by Shanghai-based CARsgen Therapeutics, satri-cel is cleared...
Late-Stage Obesity Drugs: 7 to Watch Beyond Ozempic
The weight-loss revolution that began with Ozempic and Wegovy is entering a more crowded and competitive phase, and the field of late-stage obesity drugs has become the most closely watched area in pharmaceutical research. Two recent milestones show how fast the...
Why Regenerative Medicine May Reshape the Future of Spinal Fusion
The repair and replacement of bone is a major clinical problem. The need for efficient treatments of spinal injuries, has become increasingly common and remains a significant challenge in the field of orthopedics. Regenerative medicine in bone repair is the use of...
CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune
CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
GroYourBiz Honours Canadian Clinical Leaders as “Champions of Change”
GroYourBiz (GYB), a leading organisation supporting female senior leaders and women-owned businesses, is proud to announce the recipients of its 2026 Champion of Change Award, three exceptional clinical leaders whose innovation and determination are transforming...
Weekly News Roundup | 22 June 2026
Life science news 22 June 2026: the FDA clears the first disease-modifying therapy for newly diagnosed childhood type 1 diabetes, the MHRA approves the UK's first cancer treatment delivered by on-body injector, and GSK wins approval for the first oral carbapenem...
The Role of the Microbiome in Topical Botanical Applications
The human skin is home to a complex and dynamic ecosystem of microorganisms collectively known as the skin microbiome. This microbial community - comprising bacteria, fungi, and viruses - plays a critical role in maintaining skin health, regulating immune responses,...
Beyond the Screen: Why Spinal Care Must Be Symptom-Led
In an era dominated by high-resolution diagnostics, the field of spinal care faces a profound paradox: while our ability to visualise cellular and structural anatomy has never been more advanced, the clinical efficacy of spinal interventions has not risen in tandem....
New Research Reveals How Toxic Proteins Kill Brain Cells in Dementia
Findings published in Nature Communications point to a previously uncharacterised cell death mechanism that could open new therapeutic targets for slowing neurodegeneration Researchers at King's College London and the UK Dementia Research Institute have identified a...
The ‘Wild West’ of Peptide Medicine and Who’s Qualified to Prescribe
In the medical field, being “authorized” and “qualified” are two very different things. Authorized generally indicates you have the legal right to practice. Qualified means you have the expertise, experience, and skill needed to practice effectively. The distinction...
Finding AF Before It Strikes: The Case for National Screening
There’s a concerning number of Australians living with a dangerous heart rhythm disorder - and many of them have no idea. Atrial fibrillation (AF) is a condition most people have never heard of and that’s a big problem, because it is already a silent cause of stroke. ...
Creative Biolabs Discusses Antibody Library Screening Workflow
Antibody library screening is widely used to identify antibody fragments, such as scFv, Fab, and single-domain antibodies, from large molecular repertoires. Compared with immunization-dependent approaches, library screening can be especially useful for challenging...
CAR-T Therapy Reaches Solid Tumours for the First Time
China's National Medical Products Administration (NMPA) approved satricabtagene autoleucel (satri-cel) on 22 June 2026, making it the world's first CAR-T cell therapy approved for a solid tumour. Developed by Shanghai-based CARsgen Therapeutics, satri-cel is cleared...
Late-Stage Obesity Drugs: 7 to Watch Beyond Ozempic
The weight-loss revolution that began with Ozempic and Wegovy is entering a more crowded and competitive phase, and the field of late-stage obesity drugs has become the most closely watched area in pharmaceutical research. Two recent milestones show how fast the...
Why Regenerative Medicine May Reshape the Future of Spinal Fusion
The repair and replacement of bone is a major clinical problem. The need for efficient treatments of spinal injuries, has become increasingly common and remains a significant challenge in the field of orthopedics. Regenerative medicine in bone repair is the use of...
CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune
CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
GroYourBiz Honours Canadian Clinical Leaders as “Champions of Change”
GroYourBiz (GYB), a leading organisation supporting female senior leaders and women-owned businesses, is proud to announce the recipients of its 2026 Champion of Change Award, three exceptional clinical leaders whose innovation and determination are transforming...
Weekly News Roundup | 22 June 2026
Life science news 22 June 2026: the FDA clears the first disease-modifying therapy for newly diagnosed childhood type 1 diabetes, the MHRA approves the UK's first cancer treatment delivered by on-body injector, and GSK wins approval for the first oral carbapenem...
Featured Articles
Further News
AVITA Medical Presents RECELL GO U.K. Clinical Data at BBA Annual Meeting
First U.K. case series demonstrates successful use of RECELL GO® in 17 burn and reconstructive surgery patients Findings presented at the British Burn Association Annual Meeting support the role of RECELL GO in standardizing preparation of RECELL® Spray-On Skin™ Cells...
Clinical Trials Roundup | 19 June 2026
The Menarini Group and Karyopharm Therapeutics report that selinexor plus ruxolitinib improves spleen response over standard monotherapy in the Phase 3 SENTRY trial in myelofibrosis, Agios Pharmaceuticals reinforces the anti-hemolytic profile of mitapivat with new...
Nasal Photodisinfection Cuts Surgical Infections In Complex Brain Surgery
Nasal Photodisinfection Cuts Surgical Infections In Complex Brain Surgery By 78.5% at Leeds Teaching Hospitals A pilot involving 189 patients at Leeds Teaching Hospitals using nasal photodisinfection prior to complex brain procedures performed through the nose has led...
Beyond the Injection: The Future of Holistic GLP-1 Care
The rise of GLP-1 medications has changed the conversation around obesity faster than almost anything we have seen in modern medicine. What was once dismissed as a simple issue of “willpower” is finally being recognised as something far more biologically complex....
Biotech IPO Surge: 2026’s First Half Beats 2025
The biotech IPO surge has turned 2026 into a comeback year, and one statistic captures it: in the first six months, biopharma companies raised more from initial public offerings than the entire sector managed across the whole of 2025. After a punishing multi-year...
Outcomes of a Nationwide Cardiac Screening Programme – Focusing on Females
Exciting new research presented at the annual conference of the British Cardiovascular Society (BCS): 1 - 3 June 2026 According to a new, CRY-funded study (an important subsidiary of the seminal research paper published earlier this year in the Journal of the American...
Why AI May Increase Cognitive Burden Before Reducing It
It seems that artificial intelligence is being proposed as an answer to what could be considered as one of the most serious problems facing the life sciences sector – the problem of information overload. There has never been as much data, documentation, literature,...
The Seduction of Ease: Burnout, AI, and Human Leadership in Life Sciences
Life sciences exist to do something extraordinary. Their applied solutions seek to understand biology and improve health and the quality of life for humans, animals, and plants. That is not a small mission; at its core, it is deeply human. It is the kind of mission...
CagriSema: Strong Obesity Data, but can it Beat Tirzepatide?
CagriSema, the once-weekly obesity therapy from Novo Nordisk, has spent more than a year as the most closely watched candidate in metabolic medicine. The combination of cagrilintide and semaglutide promised weight loss beyond what either molecule could achieve alone....
Improving Oncolytic Virus Development for Cancer Immunotherapy Research
Oncolytic virus development is gaining increasing attention in cancer immunotherapy research because of its ability to combine direct tumor cell killing with immune activation. Unlike conventional therapeutic strategies that focus on one pathway or one target,...
Will Artificial Intelligence Replace Medical Science Liaisons?
What Global Surveys of Medical Affairs Professionals Reveal Artificial intelligence (AI) is rapidly transforming the pharmaceutical industry, prompting many Medical Affairs professionals to ask whether some roles may eventually become obsolete. Headlines regularly...
GLP-1 Uptake by Country: Where Ozempic and Mounjaro are Booming in 2026
The global market for glucagon-like peptide-1 (GLP-1) receptor agonists has entered a new phase. What began as a breakthrough in type 2 diabetes management has become one of the defining pharmaceutical stories of the decade. In 2025, the GLP-1 receptor agonist market...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.